Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Boehringer Ingelheim
Colorcon
Baxter
Johnson and Johnson

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

Claims for Patent: 5,912,131

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,912,131
Title: Detection of type 1 collagen degradation in vivo
Abstract:Compositions useful in quantitating collagen peptides to determine the rate of bone resorption are prepared by treating bone with a protease, such as collagenase, and purifying the compositions so as to enrich them with peptides that contain 3-hydroxypyridinium cross-links.
Inventor(s): Eyre; David R. (Mercer Island, WA)
Assignee: Washington Research Foundation (Seattle, WA)
Application Number:08/965,699
Patent Claims:1. A composition comprising peptides produced by digesting bone collagen with a protease capable of generating peptides that bind to the monoclonal antibody 1H11, and then purifying the digested bone collagen to increase the concentration of peptides that contain a 3-hydroxypyridinium cross-link by at least 10-fold.

2. A composition according to claim 1, wherein the protease is bacterial collagenase.

3. A method of preparing an immunological binding partner, comprising the steps of immunizing an animal with the purified digested bone collagen composition of claim 1, and harvesting antibodies that bind to peptide fragments derived from bone collagen resorption and containing 3-hydroxypyridinium cross-links.

4. In a method of analyzing a body fluid sample for the presence or concentration of an analyte indicative of a physiological condition, comprising the steps of contacting the body fluid sample with an immunological binding partner which binds to the analyte, detecting binding of the immunological binding partner in the body fluid sample, and correlating any detected binding to the physiological condition, the improvement comprising contacting the body fluid sample with an immunological binding partner produced by immunizing an animal with the purified digested bone collagen of claim 1, and correlating any detected binding to degradation of type I collagen in vivo.

Details for Patent 5,912,131

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Advance Biofactures SANTYL collagenase VIAL 101995 001 1965-06-04   Start Trial Washington Research Foundation (Seattle, WA) 2007-11-06 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 5,912,131

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Colorcon
Boehringer Ingelheim
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.